Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

NCT01123980 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

521

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: biphasic insulin aspart 30
DRUG: metformin
DRUG: glimepiride
DRUG: insulin glargine

Sponsor

Novo Nordisk A/S